stockrow
Saturday 7 November 2026
Export NUVB’s income statement to Excel — free account
Nuvation Bio Inc.
NUVB Healthcare Biotechnology
Nuvation Bio Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.9 million, up 699.0% from fiscal 2024.
- Revenue
- +242.6%
- EPS
- +25.6%
- Free cash flow
- +34.1%
- Total debt
- +441.5%
Quarter to September 2026, against a year earlier
4.17
0.02
−0.48%
Follow NUVB
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
9.77 | 11.66 | 10.42 | 48.65 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(51.10) | (46.10) | 293.95 | (102.92) | |
P/B ratio |
8.64 | 7.80 | 4.66 | 10.01 | |
Price to Tangible BV |
9.47 | 8.13 | 4.83 | 10.39 | |
EV/Sales |
7.89 | 9.23 | 7.06 | 41.08 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(15.00) | (13.01) | (8.03) | (14.90) | |
EV/FCF |
(14.72) | (12.97) | (8.01) | (14.87) | |
Quick Ratio |
7.14 | 7.98 | 7.04 | 6.67 | |
Current Ratio |
7.45 | 8.37 | 7.44 | 6.95 | |
Net Debt/EBITDA |
9.20 | 8.22 | (101.44) | 14.36 | |
Debt/Assets |
36.67% | 33.38% | 8.70% | 8.90% | |
Debt/Equity |
1.25 | 0.98 | 0.17 | 0.17 | |
Asset Turnover |
0.29 | 0.24 | 0.26 | 0.11 | |
Operating CF/Net income |
0.92 | 0.68 | 0.94 | 0.81 | |
Capex/Depreciation |
(1.43) | (0.29) | (0.06) | (0.10) | |
Interest Coverage |
(6.90) | (7.55) | 0.58 | (5.10) | |
Research and Development Expense of Revenue |
72.70% | 96.76% | 42.11% | 81.92% | |
Selling, General and Administrative Expense of Revenue |
94.67% | 134.41% | 46.03% | 96.32% | |
Intangible Assets out of Total Assets |
0.03 | 0.01 | 0.02 | 0.02 | |
Share Based Compensation of Revenue |
22.40% | 33.01% | 10.85% | 19.08% | |
Graham Net Nets |
0.09 | 0.12 | 0.20 | 0.09 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(7.03%) | (7.65%) | (9.90%) | (6.70%) | |
Free Cash Flow Yield |
(5.49%) | (6.10%) | (8.46%) | (5.68%) | |
Revenue per Share |
0.13 | 0.09 | 0.24 | 0.12 | |
Operating CF per Share |
(0.11) | (0.12) | 0.01 | (0.09) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.11) | (0.12) | 0.01 | (0.09) | |
Cash per Share |
1.89 | 1.90 | 1.54 | 1.55 | |
Shareholders Equity per Share |
0.65 | 0.73 | 0.92 | 0.90 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.65 | 0.73 | 0.92 | 0.90 | |
Free Cash Flow |
(40.15) | (43.22) | 5.02 | (29.82) | |
Working Capital |
636.10 | 639.68 | 512.01 | 489.29 | |
Capital Expenditures |
(1.59) | (0.25) | (0.05) | (0.09) | |
Net Current Asset Value |
184.24 | 235.79 | 300.85 | 282.41 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.01 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
27.04 | 19.20 | 15.72 | 17.83 | |
Average Payables |
12.40 | 17.25 | 16.49 | 7.91 | |
Average Inventory |
10.52 | 10.23 | 7.93 | — | |
Average Assets |
689.98 | 695.86 | 551.37 | 567.72 | |
Average Common Equity |
276.93 | 313.39 | 369.51 | 384.75 |
Columns are period end dates · fundamentals updated 6 Nov 2026